106 related articles for article (PubMed ID: 15243408)
1. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer.
Baum RP; Hellwig D; Mezzetti M
Q J Nucl Med Mol Imaging; 2004 Jun; 48(2):119-42. PubMed ID: 15243408
[TBL] [Abstract][Full Text] [Related]
2. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review.
Hellwig D; Baum RP; Kirsch C
Nuklearmedizin; 2009; 48(2):59-69, quiz N8-9. PubMed ID: 19333516
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET in staging lung cancer: how does it change the algorithm?
Verhagen AF; Bootsma GP; Tjan-Heijnen VC; van der Wilt GJ; Cox AL; Brouwer MH; Corstens FH; Oyen WJ
Lung Cancer; 2004 May; 44(2):175-81. PubMed ID: 15084382
[TBL] [Abstract][Full Text] [Related]
5. [Current status of nuclear medicine clinical application of FDG-PET for cancer diagnosis. Lung cancer].
Murakami K; Nawano S; Ikeda H
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):252-7. PubMed ID: 12073630
[TBL] [Abstract][Full Text] [Related]
6. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
Cheran SK; Herndon JE; Patz EF
Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
[TBL] [Abstract][Full Text] [Related]
7. Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography.
Foo SS; Ramdave S; Berlangieri SU; Scott AM
Australas Radiol; 2004 Jun; 48(2):214-6. PubMed ID: 15230758
[TBL] [Abstract][Full Text] [Related]
8. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
9. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma.
Yoon KT; Kim JK; Kim DY; Ahn SH; Lee JD; Yun M; Rha SY; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():104-10. PubMed ID: 18087190
[TBL] [Abstract][Full Text] [Related]
10. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
11. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy.
Eschmann SM; Friedel G; Paulsen F; Budach W; Harer-Mouline C; Dohmen BM; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):804-8. PubMed ID: 12029555
[TBL] [Abstract][Full Text] [Related]
12. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
13. Value of FDG-PET in the management of non-small cell lung cancer.
Stroobants S; Verschakelen J; Vansteenkiste J
Eur J Radiol; 2003 Jan; 45(1):49-59. PubMed ID: 12499064
[TBL] [Abstract][Full Text] [Related]
14. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
16. Role of FDG-PET in the diagnosis and management of lung cancer.
Oyen WJ; Bussink J; Verhagen AF; Corstens FH; Bootsma GP
Expert Rev Anticancer Ther; 2004 Aug; 4(4):561-7. PubMed ID: 15270660
[TBL] [Abstract][Full Text] [Related]
17. PET scanning in lung cancer: current status and future directions.
Mac Manus MP; Hicks RJ
Semin Surg Oncol; 2003; 21(3):149-55. PubMed ID: 14508847
[TBL] [Abstract][Full Text] [Related]
18. [Detection of unexpected extrathoracic metastases in preoperative staging of non-small-cell bronchial carcinoma (NSCLC) with positron emission tomography (PET)].
Schmid RA; Hillinger S; Bruchhaus H; Steinert HC; von Schulthess GK; Largiadèr F; Weder W
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1264-7. PubMed ID: 9931854
[TBL] [Abstract][Full Text] [Related]
19. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Farrell MA; McAdams HP; Herndon JE; Patz EF
Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
[TBL] [Abstract][Full Text] [Related]
20. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
